| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_edc6c1a1de6f3a8176b25290c3d5417a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94a21ab88dad4df100debc715c0af1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9ccf3af76d452738fc876623d06014f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70553 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2006-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f56d119580ff9dda8e83d74d56b6da71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16243b5af91dbdbc63da2975b16609c4 |
| publicationDate |
2017-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9777054-B2 |
| titleOfInvention |
Soluble fibrin inhibitory peptides and uses thereof |
| abstract |
The present invention demonstrated that soluble fibrin binds to both Mac-1 and ICAM-1-expressing cells and inhibited adherence of these cells and immune cytotoxicity, thus inducing immune suppression in cancer. Additionally, the present invention also demonstrated that soluble fibrin enhanced metastasis in an in vivo model. Furthermore, the present invention demonstrated the utility of specific peptides that block binding of soluble fibrin to these cells as therapeutic agents in cancer progression and metastasis. It is further contemplated that these peptides can also be used to treat other diseases such as cardiovascular disease, arthritis and in many inflammatory responses where there is increased levels of soluble fibrin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021201813-A1 |
| priorityDate |
2005-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |